Pfizer (PFE)
(Delayed Data from NYSE)
$28.01 USD
-0.17 (-0.60%)
Updated May 10, 2024 04:00 PM ET
Pre-Market: $28.06 +0.05 (0.18%) 8:06 AM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Price, Consensus and EPS Surprise
PFE 28.01 -0.17(-0.60%)
Will PFE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
Top Stock Reports for Amazon.com, Visa & Pfizer
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Other News for PFE
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
'Seems Low:' Elon Musk Questions Pfizer's $0 Tax Bill, But Did Tesla Pony Up To Uncle Sam?
Microsoft, Amazon to invest billions in French tech
Cantor picks 14 undervalued biotech stocks worth a second look
Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting